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Background: Elderly patients with breast cancer are less likely to be offered surgery, partly owing to co-
morbidities and reduced functional ability. However, there is little consensus on how best to assess 
surgical risk in this patient group. 
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Methods: The ability of pretreatment health measures to predict complications was investigated in a 
prospective cohort study of a consecutive series of women aged at least 70 years undergoing surgery for 
operable (stage 1–3a) breast cancer at 22 English breast units between 2010 and 2013. Data on treatment, 
surgical complications, health measures and tumour characteristics were collected by case-note review 
and/or patient interview. Outcome measures were all complications and serious complications within 30 
days of surgery. 
Results: The study included 664 women. One or more complications were experienced by 41.0 per cent 
of the patients, predominantly seroma or primary/minor infections. Complications were serious in 6.5 per 
cent. More extensive surgery predicted a higher number of complications, but not serious complications. 
Older age did not predict complications. Several health measures were associated with complications in 
univariable analysis, and were included in multivariable analyses, adjusting for type/extent of surgery and 
tumour characteristics. In the final models, pain predicted a higher count of complications (incidence rate 
ratio 1.01, 95 per cent c.i. 1.00 to 1.01: P = 0.004). Fatigue (odds ratio (OR) 1.02, 95 per cent c.i. 1.01 to 
1.03; P = 0.004), low platelet count (OR 4.19, 1.03 to 17.12: P = 0.046) and pulse rate (OR 0.96, 0.93 to 
0.99; P = 0.010) predicted serious complications.   
Conclusion: The risk of serious complications from breast surgery is low for older patients. Surgical 
decisions should be based on patient fitness rather than age. Health measures that predict surgical risk 
were identified in multivariable models, but the effects were weak, with 95 per cent c.i. close to unity.  
  
+A: Introduction 
Breast cancer is predominantly a disease of old age, with the incidence doubling from 215 per 100 000 for 
women aged 45–49 years to 442 per 100 000 for those aged 85 years or more (England 2011)1. One-third 
of all new cases in England are diagnosed in women aged at least 70 years1. Within an ageing population, 
both the number and proportion of older patients requiring treatment at breast units is rising and set to 
continue to do so for the next 50 years2. 
 
Primary surgery (mastectomy or wide local excision (WLE) of the tumour) is the recommended 
initial treatment for early-stage breast cancer3,4. However, the percentage of women having surgery for 
breast cancer in England decreases with age, being around 90 per cent among younger age groups but as 
low as 40 per cent for patients aged 80 years or more5,6. 
UK treatment guidelines3,4 state that ‘significant co-morbidity’ may preclude surgery for patients 
with early-stage breast cancer. The increase in co-morbidity with older age may account for the lower 
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rates of surgery among elderly patients. However, although co-morbidity does explain some of the 
decline in surgical rates with increasing age, older women are still less likely to have surgery once 
adjustment has been made for co-morbidity5. Recent research suggests that adjusting for wider measures 
of health, such as functional decline/frailty, may explain lack of breast surgery for older women up to, but 
not beyond, the age of 85 years7. This provides evidence that, at least up to the age of 85 years, patient 
health, rather than chronological age, is the primary consideration when assessing surgical risk. 
However, there is little consensus on how best to assess surgical risk in older patients with breast 
cancer. Because they were precluded from earlier trials, the evidence base on older patients’ risks and 
benefits of treatment is poor8,9. A more recent older age-specific trial comparing surgery with endocrine 
therapy versus endocrine therapy alone for patients aged at least 70 years closed owing to slow 
recruitment9. Patients largely opted not to take part in this trial, in which they had a 50 per cent chance of 
not having surgery, possibly because surgery is now such an accepted mainstay of treatment for early 
breast cancer. In this context, cohort studies can help bridge the knowledge gap by identifying 
pretreatment health measures that predict surgical complications. 
One such large cohort investigating surgical risk assessment, for all ages and types of surgery, 
combines measures used within preoperative assessment, such as co-morbidity and body mass index 
(BMI), into predictive models. The US-based National Surgical Quality Improvement Program (NSQIP)10 
has developed a universal measure of surgical risk based on all surgical procedures at 393 enrolled 
hospitals. Multivariable models of mortality and morbidity are based on 21 preoperative measures 
recorded in the data set. Model discrimination is good (area under the curve (AUC) exceeding 0.8), thus 
presenting a considerable step forward in risk stratification for surgical patients in general.  Limitations of 
this risk tool include restriction to preoperative measures recorded in the data set, and lack of disease- and 
procedure-specific preoperative measures such as type and extent of surgery11. Underestimation of 
complication rates in the NSQIP data set has also been reported. This may be due to lack of inclusion of 
procedure-specific complications and inclusion of only academic hospitals enrolled in this quality 
improvement programme, which have better surgical outcomes than those in the rest of the USA11,12.  
International generalizability is also questionable owing to differences in healthcare systems. Hence 
NSQIP is likely to increase interest in risk stratification in other countries12. 
Surgical risk assessment specifically for older patients with cancer has been developed to 
incorporate measures of functional decline and frailty as well. The Comprehensive Geriatric Assessment 
(CGA) comprises a battery of various health status and functional tests recommended by the International 
Society for Geriatric Oncology as essential to treatment decision-making with older patients with cancer. 
However, there is a lack of consensus on which health measures best predict risk and therefore should be 
included in a CGA13. Functional status and fatigue have been found to predict surgical complications 
4 
 
among generic cancer patients14. However, as risk varies considerably for different types of surgery, there 
is a need to identify health measures that predict surgical risk within specific cancer groups15.  
As part of a wider research programme, a prospective cohort study was undertaken to investigate 
the extent to which the lack of surgery for patients aged at least 70 years with breast cancer is explained 
by patient choice or poor health7. This paper reports the secondary aim of the study, to investigate the 
ability of a range of pretreatment health measures to predict 30-day surgical complications among the 
subset of patients who received surgery. 
+A: Methods 
This was a prospective, cohort study of a consecutive series of women aged 70 years or more undergoing 
surgery for operable (stage 1–3a) breast cancer at 22 breast units, predominantly in north-west England, 
over 33 months (2010–2013). Data on treatment, surgical complications, a range of preoperative health 
measures and tumour characteristics were collected by case-note review and/or patient interview7. Ethical 
approval was granted by the National Research Ethics Service (10/H1014/32 and 33). 
The primary outcome measure was complications within 30 days of primary surgery (mastectomy 
or WLE) for operable (stage 1–3a) breast cancer. All patients were followed up for 90 days after 
diagnosis. Patients who did not have primary surgery within 90 days of diagnosis were not included in 
this study. As initial WLE may be followed by mastectomy, patients were classified as receiving 
mastectomy or WLE based on the most extensive primary surgery. Similarly, axillary node procedure was 
based on the most extensive dissection. Two measures of complications were used, reflecting both the 
type and impact of complications: a count of all complications and patients with serious complications. 
All complications occurring within 30 days of the last primary surgery were recorded. Non-infectious 
complications were based on a checklist developed from the East Anglian Hip Fracture Audit16 and the 
Preoperative Assessment of Cancer in the Elderly project14, with breast surgery-specific items17,18. 
Infectious complications were based on the national prevalence survey of hospital acquired infections19. 
Seromas were included only if drainage was recorded clinically, thus reflecting a greater clinical impact. 
In addition, non-drained seromas are subject to under-reporting, particularly if only seen in the primary-
care setting. Complications occurring after the start of adjuvant radiotherapy or chemotherapy were not 
included. Patients were classified as having serious complications if they had complications (other than a 
seroma or primary/minor infection) that warranted readmission as an inpatient, delayed discharge or other 
procedure. Delayed discharge was defined by being in excess of the median length of stay20 and the 
maximum time limits reported as ‘usual’ in national National Health Service (NHS) patient information 
sources21:  more than 1 day for WLE and 5 days or more for mastectomy. Other procedures included as 
indicating a serious complication were return to the operating theatre, treatment for confirmed hospital-
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acquired methicillin-resistant Staphylococcus aureus infection, stroke or pulmonary embolism, extensive 
wound repair (excision of necrotic tissue, suturing, wound packing) and blood transfusions. 
Explanatory variables were: age, measures of health, tumour characteristics, demographics and 
hospital resources. A range of health measures were recorded both from self-report at a patient interview 
undertaken within 2 weeks of diagnosis and before surgery, or from preoperative assessment as recorded 
in the case notes (Table 1); they represent patients’ functional/health status and health-related quality of 
life, co-morbidity (illnesses in addition to breast cancer22) and other clinical measures recorded at the 
preoperative health assessment. Self-reported measures were selected primarily based on ease of 
administration, validity, reliability, acceptability to older people31,32, and prediction of treatment 
received33,34 and/or treatment outcomes13–15. Clinical measures recorded at preoperative assessment were 
also considered if data were available for at least 85 per cent of the sample. Classification of blood results 
was based on the national Pathology Harmony standardization project35,36. 
Pretreatment tumour characteristics (tumour size, stage, grade, nodal and steroid receptor status) 
were recorded based on clinical, imaging and fine-needle/core biopsy assessments (cTNM 
classification29). 
 Socioeconomic class was measured using the Office for National Statistics Socio-Economic 
Classification30; it was based on main occupation before retirement if retired, and the highest 
classification if the participant was married or living with a partner. Ethnicity was recorded based on UK 
census classification categories37.  Of the 22 breast units in the study, 19 were in north-west England, two 
in London and one in the Midlands.  
+B: Inclusion criteria and patient accrual 
Women aged 70 years or more with early-stage breast cancer (stage 1–3a), having primary surgery within 
90 days of diagnosis of a new episode of operable invasive breast cancer, were offered inclusion. Women 
aged 70–74 years were included as a reference group, as previous research6,38–40 indicated that surgical 
complications may increase and surgical rates decrease from the age of 75 years. Carcinoma in situ, stage 
3b, metastatic and recurrent breast cancers were not included as the standards for operable breast cancer 
do not apply3,4. Men were not included as less than 1 per cent of all invasive breast cancers occur in men1 
and surgical management may differ3,4. Screening and accrual processes are reported elsewhere7.  
+B: Data collection  
Patients who agreed to take part were interviewed within 30 days of diagnosis and before surgery took 
place.  Information on demographic variables and measures of health detailed above was collected at this 
interview. The case notes of each patient were reviewed up to 3 months after diagnosis, using a pro forma 
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developed to collect data on tumour characteristics at diagnosis, treatments undertaken, co-morbidity and 
complications. Inter-rater agreement levels for the pro forma items satisfied the  more than 0.6 criterion, 
indicating substantial to perfect agreement41. Some 3 per cent of case-note review pro formas and 8 per 
cent of patient interviews were tested for data input errors. Error rates per data item were below 0.5 per 
cent so no further data checking was warranted. The pro formas of patients with complications were 
assessed initially by two authors independently against the above criteria for serious complications 
devised with two other authors. Disagreements were resolved by consensus with any final outstanding 
decisions made by the latter two authors. 
+B: Statistical analysis 
Explanatory variables were investigated in univariable analysis using Pearson’s χ2 test, Fisher’s exact test, 
χ2 test for trend and univariable regression analyses (two-tailed with α = 0.05). The distribution of 
continuous variables was assessed for normality using the Shapiro–Wilk W test. Associations between 
non-normally distributed variables and categorical data were investigated using the non-parametric two-
sample Wilcoxon rank sum (Mann–Whitney test) and Kruskal–Wallis equality-of-populations rank test. 
Associations for normally distributed variables were investigated using the two-sample t test. Owing to 
the large number of health measures tested for univariable associations with complications, significance 
was considered after a Bonferroni adjustment for multiple testing had been made. 
Independent variables found to be significantly associated with outcomes in univariable analyses 
were used as independent variables in the subsequent multiple regressions (forward stepwise). Models 
were built in line with the data analysis plan agreed a priori with the project’s Independent Data 
Monitoring Committee, modifying an approach suggested by Hosmer and Lemeshow42. Type of surgery 
(mastectomy versus WLE) and extent of axillary node surgery formed the base models based on clinical 
relevance and previous literature11,43. Remaining variables were initially tested against the null model and 
retained based on: the difference between the model with the additional variable and the previous model 
using the likelihood ratio test (analysis of deviance); or producing a significant coefficient in the model 
(both at a 5 per cent significance level). Explanatory variables were considered in three groups and added 
into the model in order of importance to the secondary aim of the study: health measures, 
sociodemographics and then tumour characteristics. Within each group the order in which variables were 
added into the model was determined by minimizing Bayesian information criterion (BIC) values of each 
variable added into the model individually. Variables with lower BIC values were added in sequentially, 
starting with the variable giving the lowest value. At each step an individual variable’s contribution to the 
model was assessed using the above two criteria. To reduce the likelihood of multicollinearity, and to 
ensure the number of cases in the model could sustain the potentially large number of health measures, 
they were retained in the model only if they produced both a significant coefficient and likelihood ratio 
7 
 
test. Tumour characteristics and sociodemographic variables were retained if they had a significant 
likelihood ratio test only.  
Once each group of variables had been added, variance inflation factors were checked and 
variables exhibiting factors above 10 investigated to prevent multicollinearity44. Logistic regression 
models were tested for goodness of fit (Hosmer and Lemeshow) and discrimination (area under the 
receiver operating characteristic (ROC) curve). Variables included in the final models were tested for 
two-way interactions.  
A sensitivity analysis was conducted by additionally performing backwards stepwise regression; 
this approach led to comparable final models and therefore suggested robust results. 
Data were analysed using Stata® version 12.1 (StataCorp LP, College Station, Texas, USA)45. 
+B: Sample size 
The sample size was determined a priori by the study’s primary aim, as reported elsewhere7. To test the 
aim reported in this paper, the recommended sample size was determined by the number of explanatory 
variables included in the multivariable models predicting the two complication outcome measures. 
However, the sample size of 664 should also be sufficient to support negative binomial (predicting count 
of complications) as the sample size ≥ 50 + 8p and ≥ 104 + p (where p is the number of explanatory 
variables)46. Logistic regression (predicting serious complications) should have around ten cases for each 
explanatory variable for both categories of the dependent variable47,48, although in other scenarios it has 
been shown that five cases for each explanatory variable is sufficient49. To help meet this guidance, health 
measures with non-significant coefficients (at the 5 per cent level) were dropped from the model once the 
total number of variables exceeded this limit during the model building process. In practice, only one 
health measure was lost from the model for this reason and the resulting final logistic regression model 
included five explanatory variables (8 events per variable).  
+A: Results  
Eight hundred patients aged at least 70 years were recruited into the main study investigating the extent to 
which patient health and choice explain lack of surgery; of these, 664 (83.0 per cent) had primary surgery 
within 90 days and were therefore included in the analyses of prediction of surgical complications 
reported here. One-half (329, 49.5 per cent) had a mastectomy and one-half (335, 50.5 per cent) WLE; 
38.7 per cent were aged 70–74 years, 30.3 per cent 75–79 years, 19.1 per cent 80–84 years and 11.9 per 
cent were aged 85 years or more (Table 2).  The sample was predominantly of professional/intermediate 
social class and white ethnic group. More than half were treated at a district general hospital rather than a 
university teaching hospital. Some 44.1 per cent had stage I disease recorded at diagnosis; the remaining 
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55.9 per cent had stage II or IIIa tumours, and were therefore regarded as having early operable breast 
cancer50. Over two-thirds of the patients (70.3 per cent) had no nodal involvement recorded at diagnosis 
and 56.3 per cent had small tumours no larger than 20 mm. The vast majority of participants were steroid 
receptor-positive for either oestrogen or progesterone receptors (83.6 per cent). 
+B: Complication rates 
Of the 664 women, 272 (41.0 (95 per cent c.i. 37.2 to 44.7) per cent) had some form of complication 
within 30 days of surgery (Fig. 1). However, only 145 (21.8 (18.7 to 25.0) per cent) had complications 
other than seroma, predominantly related to wound infection at the surgical site. The number of 
complications experienced by women varied from 0 to 5 (mean(s.d.) 0.58(0.85)) (Table 3). In 43 women 
(6.5 (4.6 to 8.4) per cent) complications warranted delayed discharge, readmission to hospital or further 
procedure, and were classified as serious complications. 
+B: Univariable analyses 
Participants who underwent mastectomy had a higher mean number of complications (P < 0.001), but 
were no more likely to have serious complications (P = 0.139) than those having WLE (Table 2). 
Similarly, those undergoing more extensive axillary node procedures had a greater number of 
complications (P < 0.001) but were not significantly more likely to experience serious complications (P = 
0.087). No association was found between number of complications and age (P = 0.512), and the number 
of complications did not increase significantly with each year of age (incident rate ratio (IRR) 1.02, 95 
per cent c.i. 1.00 to 1.04; P = 0.109). Although the proportion experiencing serious complications 
increased from 4.3 per cent for patients aged 70–74 years to 10.1 per cent for those aged at least 85 years, 
this effect failed to reach statistical significance at the 5 per cent level, regardless of whether age was 
measure in groups (P for trend = 0.061) or continuously (P = 0.060, two-sample t test with equal 
variances). Participants presenting with larger (P = 0.009), later-stage (P = 0.001) tumours and nodal 
involvement (P < 0.001) had a larger number of complications. However, no tumour characteristics were 
associated with serious complications. 
+B: Health measures  
Of the 46 separate health measures tested (Table 1), 14 were found to be univariably associated with 
number of complications and 19 with serious complications at the 5 per cent level (Tables 4 and 5). 
Bonferroni’s adjustment51 (applied at α/n = 0.05/46 = 0.001) was also considered. 
Among the categorical measures of health (Table 4), smoking status, blood pressure and cognitive 
impairment (Six-Item Cognitive Impairment Test) had no association with postoperative complications. 
At the 5 per cent significance level, a BMI indicative of obesity or underweight was associated with a 
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higher count of all complications, but not serious complications. A dependent Eastern Cooperative 
Oncology Group (ECOG) Performance Status and abnormal haemoglobin level were associated with both 
total and serious complications. Co-morbidity (Charlson index), a high American Society of 
Anesthesiologists (ASA) risk score and low platelet count were associated with serious complications 
only. However, none of these measures retained significance once Bonferroni’s adjustment was applied at 
0.1 per cent. 
Of the continuous measures of health (Table 5), lack of functional ability to undertake both basic 
activities of daily living (ADL) (for example self-care/hygiene) and more advanced ‘instrumental’ 
activities (such as shopping/cooking) predicted increased count of all, and odds of serious, complications 
at the 5 per cent level. However, only instrumental ADL’s prediction of complication count retained 
significance at the 0.1 per cent level. Similarly, better physical health status, as measured by the Short 
Form 12 (SF-12®; QualityMetric, Lincoln, Rhode Island, USA) Physical Component Summary, predicted 
a lower complication count at the 0.1 per cent (Bonferroni adjusted) level, but predicted lower odds of 
serious complications only at the 5 per cent level. Of the 15 European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire (EORTC QLC) C30 health-related quality-of-life 
domains, ten were associated with complications at the 5 per cent level. However, for most of the 
domains, the 95 per cent c.i. were close to unity (indicating a weak effect) and only four domains were 
significant at the 0.1 per cent level; better physical and role function predicted a lower count of all and 
serious complications, and increased pain and fatigue predicted a higher count of complications and 
serious complications respectively. 
However strongly preoperative health measures are associated with complications univariably, 
multivariable analyses are needed to establish the extent to which the health measures continue to predict 
complications once the effects of potential confounding variables have been adjusted for. Therefore, all 
health measures that significantly predicted complications at the 5 per cent level were considered for 
inclusion in multivariable analyses adjusting for a range of variables (including extent of surgery, 
sociodemographics and tumour characteristics).  
In the multivariable analyses, a higher count of complications was predicted for women 
undergoing a mastectomy compared with WLE (IRR 1.64, 95 per cent c.i. 1.27 to 2.12; P < 0.001) and 
more extensive axillary node surgery as opposed to sentinel node biopsy (IRR 1.43, 1.13 to 1.82: P = 
0.003) (Table 6). Of the health measures, only increased pain predicted outcome, with the total number of 
complications increasing by 1.01 (95 per cent c.i. 1.00 to 1.01; P = 0.004) for each point increase 
(indicating worsening pain) on the EORTC QLQ-C30 pain scale.  
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Neither type of primary surgery nor extent of axillary node procedure predicted odds of serious 
complications in the multivariable logistic regression analysis (Table 7). Three health measures retained 
in the model predicted serious complications significantly. Patients with an abnormally low platelet count 
had over four times the odds of serious complications compared with patients who had a normal or high 
platelet count (odds ratio (OR) 4.19, 95 per cent c.i. 1.03 to 17.12; P = 0.046). The odds of serious 
complications decreased with higher pulse rate (OR 0.96, 0.93 to 0.99; P = 0.010) and increased by 1.02 
(1.01 to 1.03) times for each point increase on the EORTC QLQ-C30 fatigue domain (indicating 
worsening fatigue) (P = 0.004). There was no significant difference between the observed and final model 
predicted values (goodness-of-fit test χ2 (Hosmer–Lemeshow) = 7.34, 8 d.f., P = 0.500) and model 
discrimination (AUC 0.745) was considered ‘acceptable’42. However, even when the model’s probability 
cut-off point (0.5 by default) was set to 0.063, maximizing sensitivity and specificity, these were still low 
(71.9 per cent) and the false-positive and -negative rates high (28.1 per cent). In addition, the 95 per cent 
c.i. for all four health measures predicting complications in both final models were close to unity, 
indicating weak effects. 
+A: Discussion 
Although a large proportion (41.0 per cent) of the older women in this study experienced one or more 
complications, these were predominantly seroma or minor infections. A relatively low percentage (6.5 per 
cent) experienced serious complications, which necessitated delayed discharge, readmission or further 
procedures. Only one person died (major cause septicaemia) and the frequency of life-threatening 
complications such as stroke and cardiac failure was low (Fig. 1). More extensive primary and axillary 
node surgery were associated with a greater number of all complications, but not serious complications. 
Older age did not predict an increase in risk of complications. Several health measures were associated 
with complications in univariable analysis. In the multivariable analyses self-reported pain predicted a 
higher count of all complications, whereas fatigue, along with low platelet count and pulse rate predicted 
serious complications.   
Previous studies11,54 reported a wide range of overall rates of breast surgery complications from 2 
to 50 per cent. At the higher end of this range, the present estimates are similar to those in previous 
studies of older patients with breast cancer17,55,56; for example, Chatzidaki and colleagues55 reported 
overall and major complication rates of 37.1 and 5.7 per cent respectively. Although other studies of older 
patients with breast cancer documented somewhat lower overall complication rates (between 18 and 26 
per cent38,39,57), considerable variation across studies is to be expected depending on co-morbid 
conditions, time period of data collection and follow-up, completeness of data sources, as well as the 
definition and assessment of complications. Rocco and co-workers39 highlighted that their estimated 
complication rate of 18.2 per cent among patients aged 65 years and over with breast cancer may have 
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been low owing to the use of retrospective records from 1997 to 2012. However, attempts to benchmark 
breast surgery complication rates have been reported elsewhere43,55. The aim of the study reported here 
was to investigate predictors of surgical risk among older women with breast cancer. In doing so, two 
outcome measures were used: a count of complications overall as well as the impact of more serious 
complications, reflecting the importance of capturing both aspects of surgical risk within an older 
population in which surgical recovery may be of particular concern58. 
Consistent with previous studies11,38,43,55, more extensive surgery, both in terms of type of primary 
surgery (mastectomy versus WLE) and axillary node dissection, strongly predicted a higher count of all 
complications. Conversely, the extent of surgery did not predict serious complications. This appears to 
contradict the findings of Chatzidaki et al.55 that greater extent of surgery predicted major complications. 
However, the small number of patients experiencing major complications (8 of 140 participants) limits 
the generalizability of Chatzidaki and colleagues’ findings. In addition, the effect of extent of surgery on 
all complications may be driven largely by wound complications, which have been found to be strongly 
associated with extent of surgery11,43. Wound complications make up a large proportion of complications 
overall54 but were under-represented in the present measure of serious complications, which included 
only secondary/major wound infections.  
Older age predicted neither number nor seriousness of complications. Although older age has been 
found to predict breast surgery complications in earlier59,60 and smaller39 studies, many other 
investigations reported no association11,17,43,56,57. Notably, in the US-based NSQIP cohort43, older age did 
not predict wound complications after breast surgery in either the 3107 patients with breast cancer treated 
from 2001 to 2004, or in the follow-up study11 of 26 988 patients treated from 2005 to 2007.  The authors 
argued that employing multivariable analyses and controlling for a variety of potentially confounding 
preoperative factors enabled them to demonstrate this in a large and diverse cohort of patients11. 
However, de Glas and colleagues38, in a cohort of 3179 patients diagnosed with breast cancer from 1997 
to 2004, found that women aged at least 85 years had 1.58 (95 per cent c.i. 1.14 to 2.16) the odds of one 
or more complications following breast surgery compared with those aged 65–69 years, after adjusting for 
co-morbidities, type of surgery and tumour stage.  Hence an increased surgical risk for older patients with 
breast cancer cannot be ruled out, albeit one of small magnitude limited to the oldest patients. 
Several preoperative health measures predicted complications in the univariable analyses. As in 
previous studies, co-morbidity38,39,55, BMI11,43,55, ASA risk score14,55 and functional status14 (as measured 
by ADL and ECOG Performance Status) demonstrated some association with surgical risk at the 5 per 
cent level. These findings are far from consistent, with other studies finding no association between 
surgical risk and co-morbidity14,57, BMI38,39, ASA grade11 and functional status43. Smoking status showed 
no association with surgical complications in the present study. Although the weight of literature indicates 
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that smoking predicts surgical complications from breast surgery11,38,39,61, this finding is not universal17,43. 
For example, El-Tamer and colleagues43 investigated the influence of a range of patient variables among 
3107 patients with breast cancer and found that smoking had no significant association with postoperative 
wound complications. 
Predictors of surgical risk identified from studies testing large numbers of preoperative measures 
may only reach statistical significance because of the increased chance of finding an association the 
greater the number of variables tested. Raising the significance level in line with the total number of 
variables tested can adjust for this effect (for example Bonferroni’s adjustment)51. Although there are 
examples of previous studies38,43,55 investigating risk prediction of large numbers of preoperative 
measures for breast surgery, none of the papers cited made either Bonferroni or similar adjustments. In 
the present study, once Bonferroni’s adjustment had been applied, only six of the 22 preoperative 
measures that significantly predicted surgical complications at the original 5 per cent level remained 
significant at the adjusted 0.1 per cent level. Consistent with a previous study investigating surgical risk 
of solid tumours14, increasing dependence in instrumental ADL (such as shopping and housework) 
predicted complications along with the SF-12® measure of physical health status and four domains of the 
EORTC QLC-C30 (pain, fatigue, physical and role function). These measures were originally selected 
into the main study on ability to predict treatment7,34, and/or their high validity/reliability, particularly in 
older populations31, yet they displayed stronger associations with surgical complications than many of the 
traditional preoperative health measures. Moreover, pain and fatigue predicted complications in the final 
multivariable models, although many health measures failed to do so. 
Few previous studies have undertaken similar multivariable analyses specifically predicting risk of 
breast surgery11,38,43. However, similar to the present findings, Audisio and co-workers14 reported that 
moderate–severe self-reported fatigue increased the risk of complications from surgery for solid tumours 
among patients aged at least 70 years, after adjustment for type/stage of tumour, operative severity, and 
patient age and sex. Fatigue may also increase the impact of complications (such as delay discharge), as 
suggested by the present measure of serious complications. Generalized neuropathic preoperative pain has 
been found to be predictive of postoperative pain after surgery for breast cancer62 but has not previously 
been investigated regarding other complications. Conceivably, self-reported pain may be acting as a 
proxy indicator of poorly managed/symptomatic co-morbidities. In contrast to the present results, El-
Tamer et al.43 found no association between platelet counts and wound complications after breast surgery, 
in analyses adjusting for a range of tumour characteristics, sociodemographics and other preoperative 
health measures. This inconsistency may be due to the difference in outcome measures as primary/minor 
wound infections were not included in the measure of serious complications here.  Lower preoperative 
pulse rate, as a continuous measure, predicted serious complications, suggesting that underlying 
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conditions indicated by bradycardia (such as ischaemic heart disease) may be increasing surgical risk. 
However, when preoperative pulse rate was instead categorized as bradycardia, normal or tachycardia, 
this became borderline non-significant (P = 0.062), possibly because of the small numbers of patients 
with abnormal pulse rates. Low preoperative pulse rate may also be indicative of poorly controlled 
medication (such as antihypertensives), which may have increased the complication rate. The 
complication rate may also have been exacerbated by use of other medications; for example haematoma 
may be precipitated by the high frequency of aspirin use among older age groups.   
Although the preoperative measures retained in the final model accounted for the variation in 
complications more strongly than the health measures eliminated in the modelling process, it should be 
noted that their effects in the final model are still weak, with 95 per cent c.i. around estimates close to 
unity. Moreover, although discrimination of the final model predicting serious complications (AUC 
0.745) is classified as statistically ‘acceptable’42, sensitivity and specificity only just exceed 70 per cent 
and false-positives/negatives are far from clinically acceptable, with this model failing to predict 
complications, and incorrectly predicting complications, in almost 30 per cent of patients. Further 
research is clearly needed to identify and confirm strong predictors of surgical risk for older patients that 
demonstrate clinically acceptable levels of discrimination. 
A large number of initially significant health measures were narrowed down to relatively few 
predictors in the final model. Although somewhat disappointing, it can be argued that this is the result of 
a thorough statistical process that should be employed particularly when developing tools for clinical use. 
As potential users of such risk prediction tools, clinicians should be wary and ensure that the claimed 
prediction of such assessments are not due to multiple testing, without correction for the increased chance 
of finding a significant effect, that multivariable analyses (adjusting for potential confounders) were 
undertaken, and that sensitivity/specificity as well as overall discrimination are reported. No previous 
literature investigating prediction of complications from breast surgery met all these criteria. As part of 
the US-based NSQIP, El-Tamer and colleagues43 work comes closest, reporting a similar reduction in 
variables in the final model and model discrimination just slightly lower than that of the present model 
(AUC 0.709 versus 0.745).  
The strengths of this study include the large sample size (adequate to predict risk with the 
necessary degree of precision), the range of potential predictors (including health measures collected 
before surgery), robust statistical analyses and the collection of data across 22 English breast units 
including a diverse population of 664 patients who received surgery from a cohort of 800 women7. 
However, collection of data on this scale presents inevitable limitations. Data on complications were 
collected primarily from case-note review and thereby restricted to the completeness of this data source. 
However, the outcome measures of complications used here go beyond the proportion having 
14 
 
complications predominant in other large-scale studies14,38,39, and encompass the impact of more serious 
complications on surgical recovery, which may be of particular concern for older patients with breast 
cancer58. 
This study was restricted to analyses of the secondary outcome of an existing cohort7 and as such 
was limited to the sample size, geographical area and preoperative health measures included in the main 
study. Therefore, measures such as polypharmacy, social support/networks, not initially included, could 
not be investigated but may have influenced complications and delayed discharge. Only patients who had 
surgery were included in this study, which therefore represents an analysis of complications in patients 
already selected for surgery. However, as the outcome is complications from surgery, this is inevitable 
and common to previously published studies on surgical risk11,14,38,39,55; it is not clear that it makes sense 
to include patients who have not had surgery in an analysis of surgical complications. Only patients aged 
at least 70 years were included. However, previous research6,38,39,40 indicates that surgical complication 
rates increase and rates of surgery decrease from the age of 75 years. The present cohort should therefore 
include the age group in which assessment of surgical risk is most crucial. Other limitations of the main 
study are discussed elsewhere7. Of most relevance to the analysis reported here is the under-
representation of women aged 85 years and over, limiting the generalizability of these findings to the 
oldest age group. However, under-representation of the oldest patients in any study requiring patient 
consent is likely as capacity for informed consent decreases with older age63. Future studies need to either 
focus on the oldest age group with ethical approval for vulnerable adults/consent by proxy, or examine a 
few preoperative health measures that most strongly predict risk within routine/large clinical data sets 
collected for all patients. 
This paper reports the results of a large prospective cohort study investigating surgical 
complications for older patients with breast cancer treated the UK, testing prediction of an unprecedented 
range of preoperative health measures and adjusting for extent of surgery, tumour characteristics and 
sociodemographics in multivariable analyses. Although subject to potential bias, no significant increase in 
surgical risk with older age was found. In line with national guidance, older patients with breast cancer 
should be given the same consideration for surgery as younger women, basing the treatment decision on 
fitness for surgery rather than chronological age4.  
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Fig. 1 Summary of complications within 30 days of breast surgery among 664 patients. Complications 
were classified as serious if they warranted readmission, further procedures or delayed discharge. *Only 
drained seromas recorded. †Based on the national prevalence survey of hospital acquired infections19; 
‡based on a checklist developed from the East Anglian Hip Fracture Audit16 and Preoperative Assessment 
of Cancer in the Elderly project14. §Patients with a low preoperative haemoglobin level (less than 11.8 g/l) 
not included unless they received a postoperative blood transfusion. ¶Both haematoma and wound 
haemorrhage was recorded in six patients with insufficient information recorded in the case notes to 
distinguish; this was counted as one complication here. #Clinically recorded in case notes but no 
confirmation on ultrasound examination. **Septicaemia was the major cause of death. MRSA, 





Table 1  Independent variables  
Type of surgery (wide local excision versus mastectomy) 
Extent of axillary node procedures (sentinel node biopsy versus axillary node surgery) 
Health measures at preoperative assessment 
Blood pressure (low, normal, high) 
Body mass index (underweight, normal, overweight, obese)* 
Smoking status (current, non-smoker)* 
Blood tests (9 both continuous and categorical)† 
Pulse (beats per min)  
Co-morbidity (Charlson index)22 
ASA physical status classification23  
Health measures self-reported/assessed at preoperative interview 
Functional status   
             Eastern Cooperative Oncology Group Performance Status24  
             Elderly Population Health Survey – activities of daily living basic/instrumental25  
Health status (Short Form 12 Physical and Mental Component Summaries)26 
Health-related quality of life (EORTC QLQ-C30; 15 separate scales)27 
Six-item Cognitive Impairment Test28 
Tumour characteristics (preoperative)29 
Tumour size  
Stage  
Nodal involvement  
Grade  
Steroid receptor status (ER- and PR-positive or -negative) 
Sociodemographics 
Age  
Socioeconomic classification30  
Type of treating hospital (university/teaching versus district) 
 
*Taken from self-report at interview if preoperative measures not reported in case notes. †Test included if 
recorded at preoperative assessment for at least 85 per cent of total sample. ASA, American society of 
Anesthesiologists. EORTC QLQ, European Organization for Research and Treatment of Cancer Quality 

































Primary surgery  
(< 90 days of diagnosis)  
N = 664 
Only complication = 
seroma# 
N = 127 
No complications 
N = 392 
Complication other than 
seroma 
N = 145 (21.8%) 
Complication 
N = 272 (41.0%) 
Infections = 104* 
94 wound infection 
81 primary, 13 secondary 
 77 minor, 17 major 
15 non wound infection 
 6 lower RTI; 3 upper RTI  
3 gastro intestinal infection  
2 UTI  
2 intravascular line infection  
1 skin soft tissue infection (MRSA)  
1 prosthetic implant infection 
1 septicaemia  
1 shingles 
Non infections = 69* 
29 anaemia† 
34 haematoma‡ 
9 wound haemorrhage‡ 
6 necrosis 
3 - stroke(1)/TIA (2) 
2 cardiac failure 
2 cognitive decline/ post-operative confusion 
2 haematemsis 
1 pulmonary embolism 
1 DVT (suspected‡)  
1 MI 
1 pressure sore (grade 2) 




Table 2 Surgery, sociodemographic and tumour characteristics by 30-day surgical complications 
 No. of 
patients  
(n = 664) 
All complications 






(n = 43) P‡# 
Primary surgery   < 0.001  0.139** 
   Mastectomy 329 (49.5) 0.80(0.95)  26 (7.9)  
   Wide local excision 335 (50.5) 0.38(0.68)  17 (5.1)  
Axillary node procedure*   < 0.001  0.087 
   Sentinel node biopsy 397 (59.8) 0.45(0.74)  19 (4.8)  
   Axillary node surgery 262 (39.5) 0.80(0.97)  24 (9.2)  
   None  5 (0.8) 0.20(0.45)  0 (0)  
Age (years)   0.512  0.061†† 
   70–74 257 (38.7) 0.55(0.81)  11 (4.3)  
   75–79 201 (30.3) 0.57(0.83)  15 (7.5)  
   80–84 127 (19.1) 0.65(0.83)  9 (7.1)  
   ≥ 85 79 (11.9) 0.65(1.04)  8 (10.1)  
Socioeconomic 
classification 




   Professional 358 (53.9) 0.60(0.85)  24 (6.7)  
   Intermediate 169 (25.5) 0.56(0.84)  8 (4.7)  
   Manual 131 (19.7) 0.55(0.79)  9 (6.9)  
   Unknown 6 (0.9) 1.00(2.00)  2 (33.3)  




   White 643 (96.8) 0.58(0.84)  41 (6.4)  
   Other 14 (2.1) 0.71(0.73)  0 (0)  
   Unknown 7 (1.1) 1.14(1.86)  2 (28.6)  
Hospital type   0.189  0.614** 
   Teaching/university 287 (43.2) 0.55(0.86)  17 (5.9)  
   District 377 (56.8) 0.61(0.85)  26 (6.9)  
Tumour stage   0.001  0.337** 
   I 293 (44.1) 0.48(0.78)  22 (7.5)  
   II and IIIa† 371 (55.9) 0.67(0.90)  21 (5.7)  
Nodal involvement   < 0.001  0.933** 
   Yes 197 (29.7) 0.72(0.87)  13 (6.6)  
   No/not recorded 467 (70.3) 0.53(0.84)  30 (6.4)  




   ≤ 20 374 (56.3) 0.52(0.81)  27 (7.2)  
   > 20, ≤ 50 260 (39.2) 0.66(0.89)  13 (5.0)  
   > 50 15 (2.3) 1.07(1.10)  2 (13.3)  
   Unknown 15 (2.3) 0.40(0.51)  1 (6.7)  




   1 112 (16.9) 0.58(0.89)  8 (7.1)  
   2 347 (52.3) 0.57(0.88)  25 (7.2)  
   3 146 (22.0) 0.59(0.73)  7 (4.8)  
   Unknown 59 (8.9) 0.64(0.92)  3 (5.1)  




   Yes 555 (83.6) 0.59(0.87)  35 (6.3)  
   No 68 (10.2) 0.62(0.83)  6 (8.8) 0.435 
   Unknown 41 (6.2) 0.51(0.71)  2 (4.9) 0.684 
Values in parentheses are percentages. *Most extensive axillary node procedure. †Includes 14 patients 
with stage IIIa disease. ER, oestrogen receptor; PR, progesterone receptor. ‡P value reported for complete 
data, unless indicated otherwise; §P value calculated including missing data. ¶Kruskal–Wallis χ2 test 


















Values in parentheses are percentages. Mean(s.d.) number of complications 0.58(0.85); variance 0.73. 
























No. of patients 
(n = 664) 
0 392 (59.0) 
1 188 (28.3) 
2 62 (9.3) 
3 14 (2.1) 
4 6 (0.9) 
5 2 (0.3) 
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Table 4 Preoperative health measures (categorical) by 30-day surgical complications 
 No. of 
patients 
(n = 664) 
All complications 






(n = 43) P‡# 
Charlson co-morbidity index   0.195  0.028** 
   0 371 (55.9)  0.53(0.79)  20 (5.4)  
   1 179 (27.0) 0.59(0.86)  9 (5.0)  
   ≥ 2 114 (17.2) 0.75(1.02)  14 (12.3)  
Body mass index (kg/m2)   0.019  0.253 
   <18.5 9 (1.4) 0.89(0.93)  2 (22.2)  
   18.5–24.9 201 (30.3) 0.48(0.78)  11 (5.5)  
   25.0–29.9 238 (35.8) 0.55(0.86)  15 (6.3)  
   ≥ 30.0 216 (32.5) 0.70(0.89)  15 (6.9)  
Smoker   0.761  0.766 
   No 612 (92.2) 0.58(0.84)  39 (6.4)  
   Yes 52 (7.8) 0.65(0.95)  4 (7.7)  




   Normal  186 (28.0) 0.56(0.78)  11 (5.9)  
   High (> 140/90) 411 (61.9) 0.59(0.84)  25 (6.1)  
   Low (< 90/60) 41 (6.2) 0.63(1.07)  5 (12.2)  
   Unknown 26 (3.9) 0.65(1.13)  2 (7.7)  




   Normal 538 (81.0) 0.58(0.85)  35 (6.5)  
   High (≥ 100) 32 (4.8) 0.41(0.56)  0 (0.0)  
   Low (< 60) 45 (6.8) 0.76(0.93)  6 (13.3)  
   Unknown 49 (7.4) 0.59(0.91)  2 (4.1)  




   0–1 476 (71.7) 0.52(0.80)  21 (4.4)  
   2–4 170 (25.6) 0.78(0.97)  19 (11.2)  
   Unknown 18 (2.7) 0.50(0.62)  3 (16.7)  




   I–II 411 (61.9) 0.57(0.82)  23 (5.6)  
   III–IV 155 (23.3) 0.70(0.95)  18 (11.6)  
   Unknown 98 (14.8) 0.47(0.80)  2 (2.0)  




   ≤ 7 (none) 518 (78.0) 0.58(0.85)  35 (6.8)  
   > 7 (mild/moderate) 76 (11.4) 0.61(0.87)  1 (1.3)  
   Unknown 70 (10.5) 0.59(0.88)  7 (10.0)  
Blood results†      




      Low 75 (11.3) 0.75(0.97)  9 (12)  
      Normal 482 (72.6) 0.52(0.80)  21 (4.4)  
      High 43 (6.5) 0.72(0.77)  5 (11.6)  
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      Unknown 64 (9.6) 0.78(1.05)  8 (12.5)  
   Platelet count   0.094 
0.055§ 
 0.042  
0.032§  
      Low 13 (2.0) 0.85(1.07)  3 (23.1)  
      Normal 555 (83.6) 0.56(0.82)  32 (5.8)  
      High 21 (3.2) 0.24(0.54)  0 (0.0)  
      Unknown 75 (11.3) 0.80(1.07)  8 (10.7)  
Values in parentheses are percentages. *Blood pressure classed as high or low based on limits for 
hypertension52 and hypotension53. †Nine blood results investigated. Only reported if significantly 
associated with complications (P < 0.050); level of neutrophils, lymphocytes, white blood cells, sodium, 
potassium, urea, creatinine therefore not reported. Blood results classification was based on the National 
Pathology Harmony standardization project35,36. ECOG PS, Eastern Cooperative Oncology Group – 
Performance Status (categories 0–5 indicate decreasing functional status); ASA, American Society of 
Anesthesiologists; 6CIT, Six-Item Cognitive Impairment Test (scale 0–28, increase indicates worse 
cognitive impairment; 0–7 indicates normal). ‡P value reported for complete data, unless indicated 
otherwise; §P value calculated including missing data. No variables retained significance once 
Bonferroni’s correction was applied at α/number of tests = 0.05/46 = 0.001. ¶Kruskal–Wallis χ2 test 










All complications – count 




P Odds ratio† P 
ELPHS ADL functional status    
   Basic ADL 661 1.37 (1.12, 1.68) 0.002 2.08 (1.25, 3.47) 0.005 
   Instrumental ADL 648 1.26 ((1.11, 1.43) < 0.001‡ 1.65 (1.15, 2.36) 0.006 
SF-12® PCS 648 0.98 (0.98, 0.99) < 0.001‡ 0.97 (0.94, 0.99) 0.006 
EORTC QLQ-C30 function scales    
   Global quality of  life 638 0.99 (0.99, 1.00) 0.002 0.98 (0.97, 0.99) 0.001 
   Physical 656 0.99 (0.99, 1.00) < 0.001‡ 0.98 (0.97, 0.99) < 0.001‡ 
   Role  652 0.99 (0.99, 1.00) < 0.001‡ 0.98 (0.97, 0.99) < 0.001‡ 
   Cognitive  652 0.99 (0.99, 1.00) 0.028 –  – 
   Social  643 0.99 (0.99, 1.00) 0.001 –  – 
EORTC QLQ-C30 symptom scales    
   Fatigue 652 1.01 (1.00, 1.01) 0.001 1.02 (1.01, 1.04) < 0.001‡ 
   Pain 655 1.01 (1.00, 1.01) < 0.001‡ 1.01 (1.00, 1.02) 0.025 
   Dyspnoea 655 1.01 (1.00, 1.01) 0.003 1.01 (1.00, 1.02) 0.027 
   Constipation 652 –  – 1.01 (1.00, 1.02) 0.026 
   Appetite loss 654 – – 1.01 (1.00, 1.02) 0.044 
Pulse (beats/min) 615 – – 0.96 (0.93, 0.98) 0.002 
Blood results      
   Sodium (mmol/l) 613 – – 0.89 (0.82, 0.98) 0.012 
   Potassium(mmol/l) 608 – – 2.53 (1.20, 5.34) 0.015 
Values in parentheses are 95 per cent c.i. ELPHS ADL, Elderly Population Health Survey activities of 
daily living (scale 1–4; increase indicates worse functional status); basic ADL include basic self-care and 
mobility, whereas instrumental ADL include more advanced activities such as housework and shopping. 
SF-12® PCS, Short Form 12 Physical Component Summary (scale 1–100; increase indicates better health). 
EORTC QLQ-C30, European Organization for Research on Treatment of Cancer Quality of Life 
Questionnaire, version 3 (scales 1–100; increase indicates better function and worse symptoms). 
*Generated by univariable negative binomial regression; †generated by univariable logistic regression. 
‡Significance retained once Bonferroni’s correction applied at α/number of tests = 0.05/46 = 0.001. 
Health measures are reported only if significantly associated with complications (P < 0.050); the 
following measures are therefore not reported: EORTC QLQ-C30 emotional functioning, insomnia, 
financial problems, nausea/vomiting and diarrhoea; SF-12® Mental Component Summary; blood results: 
















Table 6 Multivariable negative binomial regression model predicting count of all 30-day surgical 
complications (622 patients) 





Primary surgery    
   Wide local excision 1.00 (reference)   
   Mastectomy 1.64 (1.27, 2.12) 0.212 < 0.001 
Axillary node procedure*    
   Sentinel node biopsy only 1.00 (reference)   
  Axillary node surgery 1.43 (1.13, 1.82) 0.173 0.003 
  None  0.46 (0.06, 3.50) 0.477 0.454 
EORTC QLQ-C30 global 
quality of life 
1.00 (0.99, 1.00) 0.003 0.207 
EORTC QLQ-C30 pain 1.01 (1.00, 1.01) 0.002 0.004 
Tumour size (mm) 1.00 (1.00, 1.01) 0.004 0.340 
Constant 0.37 (0.22, 0.60) 0.093 < 0.001 
 0.19 (0.06, 0.60) 0.112  
Values in parentheses are 95 per cent c.i. *Most extensive axillary node procedure. EORTC QLQ-C30, 
European Organization for Research on Treatment of Cancer Quality of Life Questionnaire (global 
quality-of-life scale: 1–100, increase indicates better health; pain scale: 1–100, increase indicates worse 
pain). †Adjusted for all other variables in the table. The following health measures had no significant 
effect in the initial multivariable model and were not included: body mass index, Eastern Cooperative 
Oncology Group – Performance Status, haemoglobin, Elderly Population Health Survey activities of daily 
living functional status, Short Form 12 Physical Component Summary, EORTC QLQ-C30 scales 
physical, role, cognitive and social functions, fatigue and dyspnoea. Tumour stage and nodal status were 





Table 7 Multivariable logistic regression model predicting at least one serious complication by 30 days 
after surgery (537 patients*) 
 
Adjusted odds ratio§ Standard error P 
Primary surgery    
   Wide local excision  1.00 (reference)   
   Mastectomy 1.04 (0.47, 2.32) 0.43 0.922 
Axillary node procedure†    
   Sentinel lymph node biopsy only 1.00 (reference)   
  Axillary node surgery 1.75 (0.80, 3.82) 0.70 0.162 
Platelet count    
   Normal/high‡ 1.00 (reference)   
   Low 4.19 (1.03, 17.12) 3.01 0.046 
Pulse (beats/min) 0.96 (0.93, 0.99) 0.02 0.010 
EORTC QLQ-C30 fatigue  1.02 (1.01, 1.03) 0.01 0.004 
Constant 0.64 (0.05, 7.75)  0.81 0.722 
    Values in parentheses are 95 per cent c.i. *Reduced numbers owing to missing data. †Most extensive 
axillary node procedure; none of the five patients who had no axillary node procedure are retained in the 
final model. ‡Retained 19 patients with high platelet count amalgamated with 555 patients with normal 
platelet count (high category omitted owing to lack of events). EORTC QLQ-C30, European 
Organization for Research on Treatment of Cancer Quality of Life Questionnaire (fatigue scale: 1–100, 
increase indicates worse fatigue). §Adjusted for all other variables in the table. The following health 
measures had no significant effect in the initial multivariable model and were not included:  
Charlson co-morbidity index, Eastern Cooperative Oncology Group – Performance Status, haemoglobin, 
Elderly Population Health Survey activities of daily living functional status, ASA grade, potassium level, 
Short Form 12 Physical Component Summary, and EORTC QLQ-C30 scales global quality of life, 
physical function, role function, pain, dyspnoea, constipation and appetite loss. Sodium level was 
removed from the model as it produced variance inflation factors exceeding 100. Goodness-of-fit test: χ2 
Hosmer–Lemeshow = 7.34, 8 d.f., P = 0.500; area under receiver operating characteristic (ROC) curve 
0.745; sensitivity and specificity 71.9 per cent, false-positive and -negative rate 28.1 per cent (probability 
cut-off point set to 0.062742). 
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